Skip to content

Breath Combined With CT for Diagnoses of Pulmonary Nodules

Assessment of the Efficacy of Breath Test Combined With Computed Tomography for Diagnoses of Pulmonary Nodules.

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04948047
Enrollment
900
Registered
2021-07-01
Start date
2021-07-10
Completion date
2022-12-31
Last updated
2022-04-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-small Cell Lung Cancer, Pulmonary Nodule, Multiple

Keywords

volatile organic compound, pulmonary nodules, predictive model, computed tomography, HPPI-TOFMS

Brief summary

Pulmonary nodules diagnosis using breath test of volatile organic compound (VOC) is in its infancy. The accuracy of VOC analysis in diagnosing malignant pulmonary nodules varies cross the published studies. The diagnosis accuracy of VOC alone is generally poor. We speculate that the accuracy of diagnosing malignant pulmonary nodules will be improved by combining breath test with chest computed tomography (CT). This study aims to establish a predictive model of malignant pulmonary nodule using bio-markers from exhaled breath and image-markers from chest CT with retrospective data from multi centers. The sensitivity, specificity and accuracy of the model will be validated prospectively.

Detailed description

Endogenous volatile organic compounds (VOCs) can be derived from many different metabolic pathways. VOCs can be transported to the alveoli through the blood circulation and expelled by exhalation. Changes in VOCs production, clearance, and alterations in lung air-blood exchange functions can lead to aberrant VOCs profiles in the exhaled breath. Testing exhaled breath has the advantages of being completely non-invasive and easy to collect, and has been considered as a perfect approach for disease diagnoses and therapeutic monitoring. Many clinical studies have found that VOCs in exhaled breath are closely related to disease status. Specific VOCs alterations have been identified in many tumors, especially lung cancer. Pulmonary nodules diagnosis using breath test of volatile organic compound (VOC) is in its infancy. The accuracy of VOC analysis in diagnosing malignant pulmonary nodules varies cross the published studies. The diagnosis accuracy of VOC alone is generally poor. We speculate that the accuracy of diagnosing malignant pulmonary nodules will be improved by combining VOC analysis with chest computed tomography. In this study, we use a highly sensitive mass spectrometry to detect exhaled VOCs of patients with pulmonary nodules. The chest CT will be used for detecting the imaging characteristics of pulmonary nodules. The pathological diagnosis of pulmonary nodules after surgical resections is selected as golden standard. This study aims to establish a predictive model of malignant pulmonary nodule using bio-markers from breath test and image-markers from chest CT with retrospective data from multi centers. The sensitivity, specificity and accuracy of the model will be varied prospectively.

Interventions

DIAGNOSTIC_TESTPathological examinations as the golden diagnosis criteria

Pathological diagnosis, as the golden standard for diagnosing pulmonary nodules, is achieved by two experienced pathologists and validated by the third senior pathologist.

DIAGNOSTIC_TESTBreath test combined with computed tomography

Exhaled breath of each participant will be collected with Tedlar bags. The volatile organic compounds will be detected by a high-resolution high-pressure photon ionization time-of-flight mass spectrometry (HPPI-TOFMS). The Imaging markers of pulmonary nodules, including the size, three-dimensional shape, and appearance characteristics, are derived from the chest computed tomography within 2 weeks before surgery resection.

Sponsors

Beijing Haidian Hospital
CollaboratorOTHER
The First Affiliated Hospital of Zhengzhou University
CollaboratorOTHER
Jiangsu Cancer Institute & Hospital
CollaboratorOTHER
Beijing Breatha Biological Technology Co., Ltd, Beijing
CollaboratorUNKNOWN
Peking University People's Hospital
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum

Inclusion criteria

1. Age \> 18 years old; 2. Pulmonary nodules with planned surgical resection; 3. Signed informed consent and agreed to participate in this study.

Exclusion criteria

1. Preoperative radiotherapy, chemotherapy, targeted therapy or other anti-tumor therapy 2. The lack of chest computed tomography within two weeks before surgery 3. A history of malignant disease within 5 years.

Design outcomes

Primary

MeasureTime frameDescription
Diagnostic sensitivity of breath test combined with computed tomography8 weeksUsing pathological diagnosis of pulmonary nodule as gold standard, diagnostic specificity of breath test combined with computed tomography will be calculated
Diagnostic specificity of breath test combined with computed tomography8 weeksUsing pathological diagnosis of pulmonary nodule as gold standard, diagnostic specificity of breath test combined with computed tomography will be calculated
Diagnostic accuracy of breath test combined with computed tomography8 weeksUsing pathological diagnosis of pulmonary nodule as gold standard, diagnostic accuracy of breath test combined with computed tomography will be calculated

Secondary

MeasureTime frameDescription
Positive predictive value of breath test combined with computed tomography8 weeksUsing pathological diagnosis of pulmonary nodule as gold standard, positive predictive value of breath test combined with computed tomography will be calculated
Negative predictive value of breath test combined with computed tomography8 weeksUsing pathological diagnosis of pulmonary nodule as gold standard, negative predictive value of breath test combined with computed tomography will be calculated

Countries

China

Contacts

Primary ContactMantang Qiu, PhD
qiumantang@163.com13915973485
Backup ContactPeiyu Wang, MM
18339979852@163.com

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026